Monkeypox vaccine safety under the microscope in congo study
NCT ID NCT05734508
First seen Feb 13, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This study checked the safety of the MVA-BN (Jynneos) vaccine in 500 adults working on a monkeypox study in the Democratic Republic of the Congo. Participants got two vaccine doses and were watched for side effects for up to 28 days after the last dose. The goal was to see how many people had serious or minor health problems after vaccination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut National de Rescherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Kole
Kole, Democratic Republic of the Congo
-
L'Hôpital Général de Référence de Tunda
Tunda, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.